New treatments for myeloma continue to come through the appraisal pipeline. In the last few months, there have been several new treatment approvals from both the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC), which is excellent news for patients. Hopefully, there will be more good news for patients throughout 2021…
The latest update to the Blood Cancer Dashboard, a resource developed in collaboration between Janssen and the Blood Cancer Alliance, has been launched. This includes the expansion of the resource to incorporate incidence and mortality data at a national and local level for Scotland, Wales and Northern Ireland, as well as the latest available waiting…
University College London has announced the launch of a new National Cancer Research Network observational study (COSMOS) that will recruit patients with MGUS (monoclonal gammopathy of undetermined significance) and smouldering myeloma to help identify the genetic and immunological changes that cause myeloma. This ground-breaking study, which is funded by Cancer Research UK and the Medical…
The Clinical Trials Research Unit (CTRU) at the University of Leeds is running a series of webinars for researchers and clinicians so they can learn all about the UKMRA-Myeloma UK-Concept and Access Research Programme (CARP) and how it supports the development of early phase myeloma trials. The webinar series will include presentations that will describe…
Myeloma UK funded research recently published in Leukemia shows that acquisition of new copy number aberrations is associated with relapse and therefore strongly supports the need for repeated molecular analysis at relapse. Chromosomal changes like copy number aberrations (structural amplifications, gains, or deletions) are a feature of myeloma. However, the relationship between copy number aberrations…
In the last couple of months, Myeloma UK has received two professional accreditations for their patient services. In November, the Myeloma Information Specialist Team received the Helplines Standard accreditation from The Helplines Partnership for the sixteenth year running. The Helplines Standard is a nationally recognized quality standard which defines and recognizes best practice in helpline…
Results from a phase III clinical trial (BOSTON) evaluating selinexor (Xpovio®) in combination with bortezomib (Velcade®) and dexamethasone for the treatment of relapsed or refractory myeloma patients have been published in the Lancet. The data provide evidence to support the use of selinexor for the treatment of relapsed or refractory myeloma patients who had received…
Myeloma UK has initiated a project to analyse the results of the England 2018 National Cancer Patient Experience Survey to better understand the myeloma patient experience. The National Cancer Patient Experience Survey provides a snapshot of patients’ experience of NHS care, from the information they receive to how well they feel their care is delivered.…
The year so far has been particularly busy for the myeloma access pipeline with four new myeloma treatments being appraised by both drug approval bodies, the National Institute for Healthcare Excellence (NICE) and the Scottish Medicines Consortium (SMC). There is also a new treatment for patients with AL Amyloidosis which has begun the appraisal process…
Myeloma UK have developed a series of Digital Infoday Sessions to continue providing information and support to patients following the cancellation of our usual Infoday events programme. The online events take place in a variety of formats, each lasting one hour. This includes panel discussions, Q & A sessions and presentations each centred around a…
